About osimertinib
Third-generation EGFR tyrosine kinase inhibitor
Used for
- Treats certain EGFR-mutated non-small-cell lung cancers, including some after surgery or chemoradiation.
Usual adult dose
80 mg by mouth once daily; treatment duration depends on the cancer setting.
Common side effects
- Diarrhea
- Rash and dry skin
- Nail changes
- Low blood-cell counts
Important warnings
- May cause lung inflammation; seek urgent assessment for new or worsening breathing problems.
- Can affect heart rhythm and heart function; monitoring may be needed.
- May cause eye problems or severe skin reactions.
- Pregnancy should be avoided during treatment and for six weeks afterward.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment and for six weeks after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for two weeks after the last dose.
Interactions
- Strong CYP3A inducers, such as rifampin, can reduce osimertinib levels.
- Some medicines that prolong the QT interval may increase heart-rhythm risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.